Description
Sumatriptan Pharmacodynamics
Sumatriptan is a specific selective agonist of 5-NT1-serotonin receptors localized mainly in blood vessels of the brain and their stimulation leads to narrowing of these vessels. Does not affect other subtypes of 5-NT-serotonin receptors (5-NT2-7). Activates the sensitivity of trigeminal nerve receptors. The therapeutic effect usually occurs 30 min after administration.
Indications
Migraine attacks with or without aura
Contraindications
– Hemiplegic, basilar or ophthalmoplegic forms of migraine;
– CHD or presence of symptoms suggestive of it;
– history of myocardial infarction;
– pharmacologically uncontrolled arterial hypertension;
– peripheral vascular occlusive disease;
– stroke or transient cerebral circulation disorder (including history);
– Severe hepatic or renal dysfunction;
– concomitant use with ergotamine or its derivatives and within 24 hours after their administration;
– use while taking monoamine oxidase inhibitors or earlier than 2 weeks after discontinuation of these drugs;
– Under 18 and over 65 years of age (efficacy and safety have not been established);
– pregnancy;
– breastfeeding (breastfeeding is possible not earlier than 24 h after taking the drug;
– congenital galactosemia, glucose/galactose malabsorption syndrome, congenital lactose deficiency;
Dosage and administration
- Orally, the tablet should be swallowed whole with water. It is necessary to begin treatment as soon as possible in case of a migraine attack. The recommended dose is 50 mg, if necessary – 100 mg.
- If migraine symptoms do not disappear and do not decrease after the first dose, this drug should not be used repeatedly for relief of the same attack.
- To stop subsequent attacks (at symptom reduction or disappearance and then resumption), it is possible to take the second dose within next 24 hours, provided that the interval between doses is not less than 2 hours.
- Maximum daily dose is 300 mg.
